Exercise of warrants and Director Dealing

RNS Number : 9666Z
Asimilar Group PLC
20 September 2022
 

The information contained in this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon publication of the announcement via a regulatory information service, this information is considered to be in the public domain.

20 September 2022

 

 

ASIMILAR GROUP PLC ('ASIMILAR' OR 'THE COMPANY')

 

Exercise of warrants and Director Dealing

 

The Board of Asimilar (AIM/AQSE: ASLR) received an exercise notice on 16 September 2022 from Mark Horrocks, a director of the Company, in respect of warrants ("Warrants") to subscribe for 3,150,000 new ordinary shares of 0.01 pence each in the Company ("Ordinary Shares").  The Warrants have an exercise price of 0.01 pence per share.

 

Following the issue of the new Ordinary Shares, Mark Horrocks & Family Interests in the Company will amount to 9,656,280 ordinary shares, representing 7.63% of Asimilar's enlarged issued share capital.

 

Application has been made to AIM and AQSE for the admission to trading on those respective markets of these new Ordinary Shares.  It is expected that admission will become effective on or around 23 September 2022.

 

Total Voting Rights

Following the issue of the new Ordinary Shares, the issued ordinary share capital of the Company will comprise 126,498,125 Ordinary Shares with one voting right per share.  The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 126,498,125. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The FCA notification in respect of the above, made in accordance with the requirements of the UK Market Abuse Regulation, is appended below. The Directors of the Company are responsible for the release of this announcement.

 

 

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mark Horrocks

2

Reason for the notification

a)

Position/status

Director

b) 

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Asimilar Group plc

b)

LEI

213800AYJZ2B8QNY7H15

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument 

Identification code

Ordinary shares of 0.01p in Asimilar Group plc

 

GB00BFX2VL54

b)

Nature of the transaction

Exercise of warrants and issue of new ordinary shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

0.01p

 

3,150,000

 

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

N/A

e)

Date of the transaction

16 September 2022

f)

Place of the transaction

Outside a trading venue

 

-Ends-

Contact details:

 

Asimilar Group plc


John Taylor

via Buchanan

 


 

Cairn Financial Advisers LLP (AIM Nominated Adviser)


Sandy Jamieson, Liam Murray

Tel: +44 20 7213 0880

 


 

Peterhouse Capital Limited  (Joint Broker)


Duncan Vasey / Lucy Williams

Tel: + 44 20 7220 9797



Oberon Capital (Aquis Corporate Adviser and Joint Broker)


Chris Crawford

Tel + 44 20 3179 5300

 


 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAXNEALLAEEA
UK 100